Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al

Arthritis Rheum. 2002 May;46(5):1408-9; author reply 1409. doi: 10.1002/art.10271.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Aged
  • Antirheumatic Agents / pharmacology*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / therapy*
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / pharmacology*
  • Lupus Erythematosus, Cutaneous / complications
  • Lupus Erythematosus, Cutaneous / therapy*
  • Receptors, Tumor Necrosis Factor
  • Remission Induction
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept